Myeloma
The latest news, research, and perspectives in multiple myeloma. Multiple myeloma is characterized by the proliferation of malignant plasma cells that accumulate in the bone marrow and produce abnormal immunoglobulin. Read more about the pathophysiology, diagnosis, staging, and treatment of myeloma.
Advertisement
The bispecific antibody was administered as a fourth-line treatment 12 years after the patient’s diagnosis.
Prior to the retrospective study presented at SOHO 2024, no study conducted a similar comparison of Dara-VTD and RVD.
The phase III KarMMa-9 trial will review the efficacy of R maintenance alone versus with ide-cel in newly diagnosed MM.
Prior research suggested that weekly carfilzomib at a dose of 70 mg/m2 plus dexamethasone can increase PFS.
The addition of daratumumab to VRd induction and consolidation induced higher rates of MRD negativity.
A single tocilizumab dose prior to initiation of teclistamab therapy effectively reduced the incidence of CRS.
Advertisement
Treatment with CELMoDs showed promising efficacy but high rates of neutropenia in patients with multiple myeloma.
Cilta-cel improved outcomes versus standard or care in myeloma, with a safety profile consistent with CAR-T therapies.
“Blood Cancer Talks" hosts are joined by Timothy Schmidt, MD, to discuss quadruplet therapy for myeloma.
Patients in the cohort of a post-hoc analysis of the phase III CARTITUDE-4 trial received two different bridging regimens.
A retrospective study compared results from daratumumab plus carfilzomib plus dexamethasone in different lines of therapy.
Patients in the trial subanalysis had previously received an immunomodulatory agent, proteasome inhibitor, and daratumumab.
The review also compiled an array of proposed solutions to meet the needs of patients and caregivers.
Myeloma experts are advocating for dose reductions of bortezomib due to improved safety and comparable efficacy.
The approval is based on results from the PERSEUS trial, in which D-VRd achieved deeper responses when compared with VRd.
Dr. Martin highlighted research in quadruplet therapy, CAR-T therapy, and bispecific T-cell engagers.
A triplet for multiple myeloma has shown promising safety and efficacy in elderly patients ineligible for transplant.
Linvoseltamab achieved on ORR of 71% and a CR rate of 50% in patients with relapsed or refractory multiple myeloma.
James Berenson, MD, of the Berenson Cancer Center, discusses the launch of the Myeloma BioBank.
Dr. Manier tells of which new phase III data he finds especially exciting in myeloma care.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.